Journal article
Evaluation of melanoma vaccines with molecularly defined antigens by ex vivo monitoring of tumor-specific T cells.
- Speiser DE Division of Clinical Onco-Immunology, Ludwig Institute for Cancer Research, Hôpital Orthopédique, Centre Hospitalier Universitaire Vaudois, Niveau 5, Aile Est, Av. Pierre-Decker 4, CH-1005 Lausanne, Switzerland. daniel.speiser@hospvd.ch
- Pittet MJ
- Rimoldi D
- Guillaume P
- Luescher IF
- Liénard D
- Lejeune F
- Cerottini JC
- Romero P
- 2004-03-06
Published in:
- Seminars in cancer biology. - 2003
Antigens, Neoplasm
Cancer Vaccines
Clinical Trials as Topic
Histocompatibility Antigens Class II
Humans
Immunotherapy
Melanoma
Skin Neoplasms
Treatment Outcome
English
Immunotherapy of melanoma is aimed to mobilize cytolytic CD8+ T cells playing a central role in protective immunity. Despite numerous clinical vaccine trials, only few patients exhibited strong antigen-specific T-cell activation, stressing the need to improve vaccine strategies. For a rational development, we propose to focus on molecularly defined vaccine components, and evaluate their immunogenicity with highly reproducible and standardized methods for ex vivo immune monitoring. Careful immunogenicity comparison of vaccine formulations in phase I/II studies allow to select optimized vaccines for subsequent clinical efficacy testing in large scale phase III trials.
- Language
-
- English
- Open access status
- closed
- Identifiers
-
- DOI 10.1016/j.semcancer.2003.09.010
- PMID 15001165
- Persistent URL
- https://sonar.ch/global/documents/189552
Statistics
Document views: 54
File downloads: